期刊文献+

注射用N'-十二烷酰异烟肼温敏凝胶的处方前研究

Preformulation study on thermosensitive injectable hydrogel of N'-dodecanoylisoniazid
原文传递
导出
摘要 目的合成异烟肼的活性衍生物N'-十二烷酰异烟肼并对其进行处方前研究,为注射用N'-十二烷酰异烟肼温敏凝胶的处方设计提供基础。方法采用~1H-NMR、LC-MS、UV和HPLC对合成的N'-十二烷酰异烟肼进行确证和纯度测定。并用HPLC法测定N'-十二烷酰异烟肼的油水分配系数、在不同溶剂中的平衡溶解度、稳定性等理化性质。结果所得的N'-十二烷酰异烟肼纯度大于99%,~1H-NMR、LC-MS、UV确证其结构正确。N'-十二烷酰异烟肼溶液在高温(60℃)和强光(4500 Lx)条件下稳定,Log P为3.48,难溶于水,在相应的溶出介质中满足漏槽条件。结论建立的分析方法准确可靠,处方前研究表明N'-十二烷酰异烟肼原料药较稳定。 Objective To synthesize the active derivative of isoniazid, N'-dodecanoylisoniazid and conduct preprescription study, and to provide reference for the formulation design of thermosensitive injectable hydrogel of N'-dodecanoylisoniazid. Methods The structure and purity of the synthesized N'-dodecanoylisoniazide were characterized by ~1H-NMR, LC-MS, UV and HPLC. The oil-water partition coefficient, the equilibrium solubility, stability and other physicochemical properties in different solvents of N'-dodecanoylisoniazid were determined by HPLC. Results N'-dodecanoylisoniazide with a purity of over 99% was successfully synthesized. The results of ~1H-NMR and LC-MS were in good agreement with the theoretical results. N'-dodecanoylisoniazid was stable at 60 ℃ and under strong light(4500 Lx), and the Log P was 3.48. It was for N'-dodecanoylisoniazid difficult to dissolve in water and the sink condition of N'-dodecanoylisoniazid could be achieved in other dissolution media. Conclusion The established HPLC method for determining the drug content and related substances of N'-dodecanoylisoniazid is accurate and reliable. The preformulation study shows that N'-dodecanoylisoniazid is stable.
作者 何青 郭彬彬 尹耀庭 丁劲松 HE Qing GUO Bin-bin YIN Yao-ting DING Jln-song(Hunan Institute for Tuberculosis Control, Changsha 410013 School of Pharmaceutical Sciences, Central South University, Changsha 410013)
出处 《中南药学》 CAS 2017年第9期1201-1205,共5页 Central South Pharmacy
基金 省科委基金项目(课题编号:2014FJ3037)
关键词 N'-十二烷酰异烟肼 处方前研究 高效液相色谱法 N'-dodecanoylisoniazid preformulation study HPLC
  • 相关文献

参考文献2

二级参考文献46

  • 1戈朝晖,王自立,魏敏吉.利福平在脊柱结核患者不同组织分布的实验研究[J].中国脊柱脊髓杂志,2004,14(12):741-744. 被引量:21
  • 2Goldring M B, Goldring S R.Osteoarthritis.Journal of Cellular Physiology, 2007, 213, 626-634.
  • 3Wieland H A, Michaelis M, Kirschbaum B J, Rudolphi K A.Osteoarthritis-an untreatable disease? Nature Reviews Drug Discovery, 2005, 4, 331-344.
  • 4Vavken P, Dorotka R.Burden of musculoskeletal disease and its determination by urbanicity, socioeconomic status, age, and sex: Results from 14,507 subjects.Arthritis Care & Research, 2011, 63, 1558-1564.
  • 5Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D.Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.European Journal of Pain, 2006, 10, 287-333.
  • 6Loza E, Abasolo L, Jover J A, Carmona L.Burden of disease across chronic diseases: A health survey that measured prevalence, function, and quality of life.The Journal of Rheumatology, 2008, 35, 159-165.
  • 7Conaghan P G, Kloppenburg M, Schett G, Bijlsma J W.Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee.Annals of the Rheumatic Diseases, 2014, 73, 1442-1445.
  • 8Loza E, Lopez-Gomez J M, Abasolo L, Maese J, Carmona L, Batlle-Gualda E.Economic burden of knee and hip os-teoarthritis in Spain.Arthritis and Rheumatism, 2009, 61, 158-165.
  • 9Jevsevar D S.Treatment of osteoarthritis of the knee: evi-dence-based guideline, 2nd edition.Journal of the American Academy of Orthopaedic Surgeons, 2013, 21, 571-576.
  • 10Fernandes L, Hagen K B, Bijlsma J W J, Andreassen O, Christensen P, Conaghan P G, Doherty M, Geenen R, Hammond A, Kjeken I, Lohmander L S, Lund H, Mallen C D, Nava T, Oliver S, Pavelka K, Pitsillidou I, da Silva J A, de la Torre J, Zanoli G, Vliet Vlieland T P M.EULAR recom-mendations for the non-pharmacological core management of hip and knee osteoarthritis.Annals of the Rheumatic Diseases, 2013, 72, 1125-1135.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部